|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCED1A |
Gene summary for PCED1A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCED1A | Gene ID | 64773 |
| Gene name | PC-esterase domain containing 1A | |
| Gene Alias | C20orf81 | |
| Cytomap | 20p13 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q9H1Q7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64773 | PCED1A | LZE24T | Human | Esophagus | ESCC | 4.55e-13 | 3.69e-01 | 0.0596 |
| 64773 | PCED1A | P1T-E | Human | Esophagus | ESCC | 3.76e-13 | 5.33e-01 | 0.0875 |
| 64773 | PCED1A | P2T-E | Human | Esophagus | ESCC | 5.11e-26 | 3.83e-01 | 0.1177 |
| 64773 | PCED1A | P4T-E | Human | Esophagus | ESCC | 5.91e-13 | 2.70e-01 | 0.1323 |
| 64773 | PCED1A | P5T-E | Human | Esophagus | ESCC | 1.48e-02 | 7.45e-02 | 0.1327 |
| 64773 | PCED1A | P8T-E | Human | Esophagus | ESCC | 7.79e-13 | 1.18e-01 | 0.0889 |
| 64773 | PCED1A | P9T-E | Human | Esophagus | ESCC | 1.01e-14 | 3.67e-01 | 0.1131 |
| 64773 | PCED1A | P10T-E | Human | Esophagus | ESCC | 3.15e-15 | 2.92e-01 | 0.116 |
| 64773 | PCED1A | P11T-E | Human | Esophagus | ESCC | 2.52e-10 | 4.13e-01 | 0.1426 |
| 64773 | PCED1A | P12T-E | Human | Esophagus | ESCC | 4.25e-21 | 3.64e-01 | 0.1122 |
| 64773 | PCED1A | P15T-E | Human | Esophagus | ESCC | 1.12e-07 | 1.40e-01 | 0.1149 |
| 64773 | PCED1A | P16T-E | Human | Esophagus | ESCC | 8.39e-24 | 5.06e-01 | 0.1153 |
| 64773 | PCED1A | P17T-E | Human | Esophagus | ESCC | 2.40e-15 | 4.83e-01 | 0.1278 |
| 64773 | PCED1A | P19T-E | Human | Esophagus | ESCC | 1.59e-07 | 3.23e-01 | 0.1662 |
| 64773 | PCED1A | P20T-E | Human | Esophagus | ESCC | 1.05e-19 | 3.91e-01 | 0.1124 |
| 64773 | PCED1A | P21T-E | Human | Esophagus | ESCC | 3.85e-12 | 2.71e-01 | 0.1617 |
| 64773 | PCED1A | P22T-E | Human | Esophagus | ESCC | 1.06e-19 | 2.35e-01 | 0.1236 |
| 64773 | PCED1A | P23T-E | Human | Esophagus | ESCC | 1.87e-13 | 3.67e-01 | 0.108 |
| 64773 | PCED1A | P24T-E | Human | Esophagus | ESCC | 3.94e-10 | 1.90e-01 | 0.1287 |
| 64773 | PCED1A | P26T-E | Human | Esophagus | ESCC | 5.27e-53 | 1.03e+00 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCED1A | SNV | Missense_Mutation | rs756545276 | c.34N>T | p.Arg12Cys | p.R12C | Q9H1Q7 | protein_coding | tolerated_low_confidence(0.11) | benign(0) | TCGA-D8-A27E-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen+anastrazolum | SD |
| PCED1A | insertion | Frame_Shift_Ins | novel | c.57_58insTTCCTCACTCGTGTTTACTCCG | p.His20PhefsTer62 | p.H20Ffs*62 | Q9H1Q7 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| PCED1A | SNV | Missense_Mutation | c.853G>A | p.Glu285Lys | p.E285K | Q9H1Q7 | protein_coding | tolerated(0.54) | benign(0.003) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PCED1A | SNV | Missense_Mutation | novel | c.1240N>T | p.Ser414Cys | p.S414C | Q9H1Q7 | protein_coding | deleterious(0) | benign(0.41) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCED1A | SNV | Missense_Mutation | rs199975004 | c.826C>T | p.Arg276Cys | p.R276C | Q9H1Q7 | protein_coding | deleterious(0) | possibly_damaging(0.708) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| PCED1A | SNV | Missense_Mutation | c.877N>T | p.Pro293Ser | p.P293S | Q9H1Q7 | protein_coding | tolerated(0.26) | benign(0) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PCED1A | SNV | Missense_Mutation | c.49G>A | p.Asp17Asn | p.D17N | Q9H1Q7 | protein_coding | tolerated_low_confidence(0.51) | benign(0) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCED1A | SNV | Missense_Mutation | c.1291N>T | p.His431Tyr | p.H431Y | Q9H1Q7 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.968) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCED1A | SNV | Missense_Mutation | novel | c.679N>A | p.Asp227Asn | p.D227N | Q9H1Q7 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCED1A | SNV | Missense_Mutation | rs755935826 | c.1346C>T | p.Ser449Leu | p.S449L | Q9H1Q7 | protein_coding | tolerated_low_confidence(0.1) | possibly_damaging(0.565) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |